Cerus (CERS) EBITDA Margin (2010 - 2026)

Cerus (CERS) posted EBITDA Margin of 3.23% for Q2 2026, down 390.32% sequentially from 0.66% in Q1 2026, and up 329.0% YoY from 0.75% in Q2 2025.

Cerus (CERS) EBITDA Margin (2010 - 2026) Analysis & Trends

Cerus has reported EBITDA Margin for 17 years, with the latest figure at 3.23% in Q2 2026.

Quarterly EBITDA Margin rose 329.0% year-over-year to 3.23% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.65% (up 482.0% YoY) and the FY2025 annual result came in at 3.71%, up 335.0% from the prior year.
EBITDA Margin eased to 3.23% in Q2 2026 per CERS's latest filing, from 0.66% in the prior quarter.
Over five years, EBITDA Margin peaked at 2.35% in Q3 2025 and troughed at 45.67% in Q1 2023.
A 5-year average of 12.18% and a median of 10.85% in 2023 frame the typical range for EBITDA Margin.
The sharpest annual moves came in 2022 and 2023: EBITDA Margin surged 4405 bps in 2022, then slumped 1937 bps in 2023.
Over 5 years, EBITDA Margin stood at 14.15% in 2022, then surged by 109 bps to 1.26% in 2023, then slumped by 259 bps to 2.02% in 2024, then soared by 63 bps to 0.75% in 2025, then sank by 331 bps to 3.23% in 2026.
According to Business Quant data, EBITDA Margin over the past three periods registered 3.23%, 0.66%, and 0.75% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	13.44%
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	25.18%
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	19.10%
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	21.65%
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	29.48%
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	24.33%
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	13.96%
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	10.30%
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	19.15%
10	Cerus	560.58 Mn	504.32 Mn	29.53 Mn	-3.23%

Download Data